Introduction
============

Renal transplantation is a better choice for treatment of end stage renal disease. However, after kidney transplantation patients need permanent immunosuppressive medication to prevent graft rejection and loss of graft. The mechanism of all current immunosuppressive drugs target T cell activation, cytokine production and clonal expansion. Cyclosporine and tacrolimus inhibits the phosphatase activity of calcineurin, thereby suppressing the production of Interleukin-2 (IL-2) and other cytokines ([@b25-btt-2-875]). The use of immunosuppressive drugs requires a fine balance between adequate immunosuppressant to prevent rejection and excessive dosage leading to toxicity.

Genetic variations in genes encoding different T-helper (Th) type 1 and Th2 cytokines, chemokines and their receptors, growth factors, molecules of the renin--angiotensin system, enzymes of the homocysteine pathway, and proteins acting as substrates of immunosuppressive drugs influence impact on success of engraftment and highlight the concept of genetic predisposition to allograft rejection ([@b11-btt-2-875]). Several studies on functional variants caused by single nucleotide polymorphisms (SNPs) in genes encoding drug metabolizing enzymes, transporters, ion channels and drug receptors have been known to be associated with inter-individual, interethnic variation in drug response and play role in influencing the efficacy and toxicity of medications ([@b12-btt-2-875]). It has been suggested that cytokine genotyping may play a predictive role in identifying individuals who are at higher risk of acute rejection by individualizing their immunosuppression levels ([@b14-btt-2-875]).

As polymorphisms segregate independently any one individual might respond with a pattern of quite different cytokine expression from another individual. Cytokine interactions are complex and it is unlikely that a single allelic variant results in either graft rejection or induction of allograft tolerance ([@b18-btt-2-875]). Heritable cytokine polymorphisms have been shown to account for differences in allograft survival. For instance, recipients of renal allograft whose genotypes predicted high tumor necrosis factor-α (TNF-α) and IL-10 production were more likely to undergo an acute rejection episode than individuals with genotypes predicting low TNF-α and IL-10 production ([@b34-btt-2-875]). High IL-6 producing individuals have previously been shown to be at heightened risk for acute rejection ([@b17-btt-2-875]). Further, [@b4-btt-2-875] observed an increase in IL-2 and IL-6 production associated with rejection events. Polymorphisms in codon 10 and codon 25 of transforming growth factor-β (TGF-β) gene result in high producer phenotype and have been associated with chronic transplant rejection ([@b10-btt-2-875]). [@b32-btt-2-875] reported absence of IL-4 T allele in both recipient and donor, ie, recipient low producer/donor low producer, was significantly increased in rejection group. We thus utilized this information in evaluating the association of IL-2, IL-4, IL-6, TNF-α, and TGF-B cytokine gene polymorphisms with the risk of allograft rejection. We further assessed the possibility of these gene variants associations with cyclosporine level in stable renal transplant recipients from the North Indian population.

Materials and methods
---------------------

### Subjects

We studied one hundred eighty-four recipients of renal transplants from a live related donor at our tertiary care hospital over a period of three years (2004--2006). Informed consent was obtained from recipients and controls participating in this study. Approval of this study was obtained from local Ethical Committee of Sanjay Gandhi PGIMS, Lucknow. Transplant patients who were HbsAg and HCV positive were excluded from study to rule out the possible cause of rejection. Patients were typed for human leukocyte antigen (HLA) A, B and DR, DQ antigen. Controls (n = 180) included healthy individuals visiting the hospital and staff/employees with no history of hypertension, diabetes, renal failure, vascular diseases, stroke/cardiomyopathy. Both patients and control groups had similar ethnicity.

### Clinical data

The demographic and clinical details have been described in [Table 1](#t1-btt-2-875){ref-type="table"}. Patients were followed for at least 2 years after transplantation. There were 34 patients (age range 19--55, M:F 28:6) with clinical and biopsy proven rejection episode (RE). All patients had single rejection episode except two, who experienced rejection more than once and one patient out of this had gone for re-transplantation. Clinical rejection was identified as an increase in creatinine levels in absence of infection, obstruction or evidence of drug toxicity, associated with a fall to within 10% of baseline creatinine level after treatment. All biopsies were reviewed by a renal pathologist, and the Banff 93 working classification criteria were used in the histological classification of biopsies ([@b33-btt-2-875]). Fifteen patients (age range 19--53, M: F 15:0) experienced delayed graft functioning (DGF) who required dialysis within the first 7--10 days of post transplantation and 135 had stable graft functioning (SGF) (age range 17--64, M:F 118:17) without episode of rejection/any infection and obstruction except one patient who had a history of cytomegalovirus (CMV) infection.

Patient's immunosuppressive therapy consisted of cyclosporine, azathioprine and corticosteriod. Daily doses of CsA were adjusted according to C-2 levels. For all patients the initial dosage of cyclosporine was 8 mg/kg/d to achieve C2 level of 1.8 μg/ml which was subsequently reduced to 1.6, 1.4, 1.2, 1.0, and 0.8 after 1, 3, 6, and 12 months. Intravenous methylprednisolone was given at a standard dosage regimen of 500 mg of at the time of surgery, 125 mg intravenously the following day and then 20 mg of prednislolone daily. Oral prednisolone was then tapered to 10 mg daily at 3 mo transplantation. There were only eight patients receiving tacrolimus and were not included in the study due to low number.

### Cyclosporine determination

Cyclosporine (C~2~) values in whole blood were assayed with Emit (Enzyme multiplied immunologic technique) 2000 (Dade Behring Inc, Deerfield, IL). Peripheral blood samples were collected after 2 hours in morning following oral administration of cyclosporine post transplantation. Patient's weight and daily dose of cyclosporine (in milligrams) were also recorded.

### DNA extraction and cytokine genotyping

Genomic DNA was extracted from peripheral blood samples collected from transplant recipients and healthy volunteers by salting out method ([@b21-btt-2-875]). SNPs in the cytokine genes were genotyped by polymerase chain reaction--restriction fragment length polymorphism (PCR--RFLP) in IL-2, TGF-β (C-del), and TNF-α −308, variable number tandem repeats (VNTR) analysis in IL-4 and amplification refractory mutatory systems (ARMS)--PCR in IL-6 and TGF-β (codon 10 and 25) as reported previously ([@b30-btt-2-875]; [@b29-btt-2-875]; [@b4-btt-2-875]; [@b37-btt-2-875]; [@b8-btt-2-875]; [@b36-btt-2-875]).

To improve the genotyping quality and substantiation, 30% of samples were re-genotyped by other laboratory personnel and results were reproducible with no discrepancy recorded in genotyping. Genotyping of 10% of samples were confirmed by DNA sequencing.

### Data analysis

Statistical analysis was performed using the χ^2^ test to compare the genotype frequency distribution in patients and controls with SPSS software (version 11.5; SPSS Inc., Chicago, IL) using Pearson chi-square or Fisher's exact test. Multinomial logistic analysis was performed to investigate the impact of multiple factors like age, gender and body weight with graft outcome. The mean concentration of cyclosporin and dosage and numerical values was tested by the Student *t*-test or ANOVA test. Univariate analysis with Bonferroni correction was performed to see the differences between groups SGF with RE and SGF with DGF. Odds ratio (OR) at 95% confidence intervals (CI) was also determined to describe the strength of association using binary logistic regression model (BLRM). For nonparametric data of cyclosporine concentration among different genotypic groups Kruskal--Wallis test was employed. To examine whether genotype frequencies were in Hardy-Weinberg equilibrium, Goodness of fit χ^2^ tests was used. Haplotype frequencies and linkage disequilibrium between each pair of TGF-β (codon-10 and 25) was determined by Arlequin (version 2.0). To analyze the haplotypes and combination of genotypes we did logistic regression analysis by keeping case-control as dependent variable and haplotype/genotypic combination as factors. *P* value \< 0.05 was considered statistically significant.

Results
=======

Association of subject characteristics
--------------------------------------

Multinomial logistic analysis was performed between RE vs SGF and DGF vs SGF to investigate the impact of set of predictor variables like recipient and donor age, gender and body weight on the outcome of allograft (ie, rejection and delayed graft functioning). The mean concentration of cyclosporin dosage and C2 levels on the rejection of allograft was tested by the ANOVA test. Significant association was seen for C2 levels at 1 month between RE and SGF (p = 0.032). However, no significant difference was observed for any of the other factors (p \> 0.05) ([Table 1](#t1-btt-2-875){ref-type="table"}).

### Association of allograft function with combined effect of degree of HLA mismatches and genotypes

Evaluation was done for HLA DR, DQ mismatches (MM) in combination with genotypes of all the cytokine genes studied in RE and SGF recipients. We excluded the DGF group as none of the cytokine genes showed any significant association or risk for rejection and also the number was too low for combined regression analysis. Recipients were divided into two groups: 0--2 MM and 3--4 MM and their interaction with genotypes was evaluated with risk of rejection using binary logistic regression analysis by taking SGF and RE as dependent variable and number of MM and genotypes as categorical. Binary logistic regression analysis of combined effect of number of DR and DQ mismatches with different genotypes showed no significant risk for the rejection of allograft ([Table 2](#t2-btt-2-875){ref-type="table"}).

### Frequency of IL-2, IL-4, IL-6, TNF-α −308 G/A and TGF-β (713-8delC, codon 10 and 25) variants in renal transplant recipients

Genotype frequency distributions are represented in [Table 3](#t3-btt-2-875){ref-type="table"}. The genotype frequency distributions did not deviate from Hardy--Weinberg equilibrium except for TGF-β codon 25. Frequency distribution in TGF-β codon 25 genotypes Arg/Arg (66.7%), Arg/Pro (23.3%) and Pro/Pro (10%) in our population was comparable to a study of [@b19-btt-2-875] and [@b35-btt-2-875] in African-Americans and Italian populations, respectively. [@b7-btt-2-875] and [@b1-btt-2-875] reported 0% frequency in mutant Pro/Pro genotype while [@b26-btt-2-875] showed 0% in both mutant as well as heterozygous genotypes and 100% in wild homozygous (Arg/Arg), signifying that this gene may have varied frequencies among different populations. Duplicate quality control DNA samples showed \>95% agreement for all genotyping. Further laboratory personnel were blinded to case--control status and to achieve \>95% accuracy in genotyping. The genotype frequencies of total number of patients were compared with controls for the cytokine genes studied to see whether any of these cytokines were associated with the end stage renal disease in patients. Significant difference in the genotypic frequencies between patients and controls were observed for IL-4, TNF-α −308 and TGF-β codon 10 (P \< 0.001, Pearson Chi-square test).

The patients were categorized into subgroups, RE and DGF and were compared with SGF to study the allograft impact pattern and the risk for rejection. Univariate analysis was performed and the p-values were adjusted by Bonferroni correction ([Table 4](#t4-btt-2-875){ref-type="table"}). Results revealed significant differences between SGF and RE in IL-4 and TNF-α −308 gene (p = 0.027 and 0.012). The frequency of high producing genotype B1B1 was 11.8% in RE, 2.2% in SGF and 0.5% in controls showing \>6-fold high risk in RE (OR, 6.815; 95%CI, 1.40−33.08; RE vs SGF; OR was calculated using Binary logistic regression analysis). Frequency of high producing genotype AA of TNF-α −308 was highest among RE as compared to SGF and controls (44.1%, 27.4% and 8.3%; p = 0.012, RE vs SGF). The AA genotype showed \>7-fold higher risk for rejection (OR, 7.905; 95%CI, 1.69−36.96; p = 0.009). TGF-β C-del showed a marginal significance (p = 0.054) and the frequency of low producing genotype C/CC of TGF-β was highest among RE showing 2.6-fold (OR, 2.677; 95%CI, 1.06−6.74; p = 0.037). Further, frequency of low producing genotype pro/pro (CC) of TGF-β codon 10 was higher in RE (38.2%) as compared to SGF (20.0%) and showed 5-fold risk for rejection (OR, 5.200; 95%CI, 1.06−25.30; p = 0.041). No significant difference was observed between patients vs controls and RE vs SGF for IL-2, IL-6, and TGF-β codon 25.

### Cytokine gene polymorphism and risk of delayed graft function

Although the number of DGF patients was quite low for analysis, however, analysis was done to see any risk of cytokine genes polymorphism associated with delayed graft functioning. DGF group was compared to SGF. The results revealed no significant association for any of the cytokines with the risk for DGF as compared to SGF.

### Effects of cytokine SNPs on cyclosporine dose requirement

We examined the relationship between each SNP of the cytokine genes and cyclosporine pharmacokinetic parameter C2 level μg/ml for 1 month in 135 stable renal transplant patients ([Table 5](#t5-btt-2-875){ref-type="table"}). A Maximum variation for adjustment for dose occurs as during first month of post-transplantation. This was a case only study and cyclosporine levels of the patients with their genotype groups were compared using Kruskal--Wallis test. Of 7 cytokine SNPs tested, two cytokines IL-2 and TGF-β codon 25 SNP were significantly associated with the dose-adjusted C2 level (*P* = 0.012, and 0.010, respectively). The C2 levels were significantly lower in patients with the high producing genotype T/T of IL-2 and heterozygous G/C of TGF-β codon 25.

### Linkage disequilibrium and haplotype distribution

The two sites codon 10 and 25 of TGF-β have been found to be in linkage disequilibrium therefore we constructed haplotypes between these two sites to see their contribution to risk of disease/rejection using Arlequin software. The reconstructed haplotypes of contols, recipients, RE and SGF were compared and risk was estimated by binary logistic regression analysis for TGF-β ([Table 6](#t6-btt-2-875){ref-type="table"}). The haplotype frequencies of TGF-β gene (codon-10 and 25) were comparable in RE, SGF and controls and none of the haplotypes showed any risk for rejection.

### Combined genotype analysis of cytokine gene polymorphisms

IL-4 and TNF-α showed significant association with rejection of allograft and cytokines are reported to show synergistic effect. We, therefore evaluated the combined inter-gene interaction of IL-4 with IL-2 and IL-6, TNF-α−308 and TNF-α (−308) with TGF-β (codon-10, 25 and C-deletion) with rejection episode taking low risk alleles combination of IL-4 (B2) with low IL-2 (G), IL-6 (C) and TNF-α −308 while high producers of TGF-β (C) as referent group using binary logistic regression analysis. Among different genotype combinations, IL-4^high^-IL-2^low^ and IL-4^high^-IL-2^high^ showed significantly a higher risk for RE (OR, 3.920; 95%CI, 1.07−14.2; p = 0.038; OR, 3.360; 95%CI, 1.03−10.9; p = 0.045, respectively) ([Table 7](#t7-btt-2-875){ref-type="table"}). Significant difference was also observed for IL-4^high^-TNF-α^308/high^ and TNF-α^308^-TGF-β^C-del^ combined genotype (p = 0.004 and .005). We observed that recipients with combination of high IL-4 and high TNF-α; TNF-α (high producer) and TGF-β (low producer) are at higher risk for rejection.

Discussion
==========

Cytokines are essential for control of immune response as most of the immunosuppressive drugs target cytokine production or their action. Inter-individual variations occur for sensitivity to different immunosuppressive drugs as manifested by either rejection or toxicity in patients with blood drug concentrations within the therapeutic range.

Cytokines have the potential to influence various immune and inflammatory responses within the graft. The difference in cytokine production between individuals is intensified in presence of human leukocyte antigen (HLA) mismatching. In our study, no significant association for DR and DQ mismatches with different cytokine genotypes for rejection was observed. Our observations complimented the findings of Capei and colleagues (2004) showing that matched grafts were lost in same proportion as the mismatched.

A significant association of high producing genotypes B1B1 of IL-4 and AA of TNF-α −308 with the allograft rejection were observed showing a higher risk for rejection. However, genotypic frequencies did not differ significantly for other cytokine gene variants in our population. To assess the reliability we showed that recipients with B1B1 gene variant of IL-4 had \>6-fold higher risk and AA of TNF-α −308 showed \>7-fold higher risk. The TGF-β C-del showed a marginal significance and the frequency of low producing genotype C/CC of TGF-β showed 2.6-fold risk. Our findings showing higher frequency of rejection episode in recipients having high producing genotype (B1B1) of IL-4 corroborate the previous observation, which opined that Th2 cytokines promote both acute and chronic allograft rejection ([@b20-btt-2-875]). IL-4 VNTR, intron 3 has not been previously reported in renal transplant patients. A recent study by [@b2-btt-2-875] reported a significant association of IL-4 --33 gene with renal allograft outcome. Strong association of TNF-α −308 polymorphism with rejection episode in our study are in accord with a study of [@b1-btt-2-875] and [@b26-btt-2-875] reporting the association of RE with AA genotype. On the contrary [@b5-btt-2-875] did not show any association of TNF-α −308 with rejection episodes. The TNF-α −308 G/A is a promoter polymorphism and AA genotype is associated with its high production. [@b6-btt-2-875] suggested that increased circulating levels of TNF-α in the rejecting kidneys trigger inducible nitric oxide synthase expression and damage to the microvascular endothelial cells, a characteristic feature of acute vascular rejection. Genotypic frequencies of IL-4, TNF-α −308 and TGF-β codon 10 differed significantly between patients and controls showing that these variations may be linked with a susceptibility to suffer from ESRD, which complimented our earlier study in ESRD patients ([@b16-btt-2-875]; [@b22-btt-2-875], [@b23-btt-2-875]).

One of the strategies used currently to overcome rejection episode was to correlate affected cytokine gene polymorphism with immunosuppressant like cyclosporine levels, a calcineurin inhibitor used for preventing allograft rejection. Its pharmacokinetic characteristics vary greatly among individuals, and daily doses are adjusted to whole-blood cyclosporine concentration.

The role of cytokines variation in cyclosporine pharmacogenetics can be well explained by a study by [@b9-btt-2-875] who opined the ability of immunosuppressive drugs to remove the negative regulatory signals for IL-2-like IL-10, due to inter-individual variation. Out of 7 cytokine SNPs tested, two cytokines IL-2 and TGF-β codon 25 SNP were significantly associated with dose-adjusted C2 level showing that C2 level was lower or possibly better absorption of cyclosporine in patients with TT genotype of IL-2 and heterozygous GC of TGF-β. This is perhaps a first report from north Indian population showing a significant association of cytokine gene variants with cyclosporine dose requirement.

Cytokines illustrate synergistic effect if the combined effect of two cytokines on cellular activity is greater than the additive effects of individual cytokine. A combined analysis of the effect of IL-4 in combination with IL-2 showed significant risk with both low and high IL-2 genotypes. Another combination of high IL-4 with high TNF-α demonstrated a significant higher risk for rejection. This observation suggested that IL-4 cytokine could have synergistic effect with TNF-A reflecting gene-gene interaction. The other combination of TNF-α (−308) with TGF-B projecting recipients with TNF-α^308/high^-TGF-β^C-del/low^ associated with higher risk of rejection. Our observations suggested that high producing genotypes of proinflammatory cytokine TNF-α and low producing genotypes of TGF-β (anti-inflammatory) may have a major impact on the immune response responsible for allograft acceptance/rejection ([@b26-btt-2-875]).

IL-2 did not show any significant association with the rejection in our population, which is in agreement to the study of [@b31-btt-2-875] and [@b27-btt-2-875] showing no association of IL-2 −330 with acute rejection after kidney transplantation. The reason behind no association of IL-2 could be that patients are given high therapeutic doses of CsA during the early period of transplantation. It is plausible that a standard high dose of CsA may be adequate for the complete blockage of IL-2 production in individuals that carry high producer IL-2 genotype thus leading to better graft survival. It is known that under conditions of allo-stimulation and immunosuppression, the influence of the T/T and T/G genotypes on IL-2 production could be different from that observed in vitro ([@b24-btt-2-875]).

IL-6 polymorphism did not reflect any association in our population. Our findings are in agreement with [@b31-btt-2-875] and [@b13-btt-2-875] showing no association of IL-6 with rejection. On the contrary [@b28-btt-2-875] demonstrated IL-6 CC genotype to be associated with an increased risk of rejection. Contradiction in results perhaps could be best resolved by functional studies that may be required to provide new insights into the role of IL-6.

TGF-β is a pleiotropic cytokine with unique and potent anti-inflammatory and there are several reports showing the protective roles of TGF-β ([@b15-btt-2-875]; [@b39-btt-2-875]). Analysis of TGF-β C-del, codon-10 and 25 revealed that low producing genotype C/CC of C-del and 'Pro-Pro' of codon-10 was significantly associated with higher risk for rejection which complimented the study by [@b26-btt-2-875].

Delayed graft function is linked to several long-term risks for acute rejection subsequently leading to allograft dysfunction and graft loss. A number of clinical factors may be linked with DGF. We did not detect significant difference in cytokine gene variants in patients of SGF and DGF, which could be related to the small number of patients studied. Our findings corroborate with the studies of [@b1-btt-2-875] and [@b28-btt-2-875] who in their study too, reported no association of different cytokines gene studied with delayed graft functioning.

Due to an high degree of LD observed between SNPs of TGF-β codon 10 and 25, disease variants may be revealed through evaluation of underlying haplotypes. Hence we constructed haplotypes for TGF-β polymorphism in our study. TGF-β gene (codon-10 and 25) haplotype frequencies were comparable in RE, SGF and controls. Haplotypic frequency of TGF-B in our population matched with the Caucasians ([@b3-btt-2-875]).

The sample size, though low, may be a limitation due to single centre, nevertheless, the results obtained from this present study constituted a preliminary step and initial understanding of the role of cytokine gene polymophism in renal transplant. Hence, further analyses in large multicenter allograft series are warranted.

Conclusion
==========

Strong associations of high producing genotypes B1B1 of IL-4 and AA of TNF-α −308 while low producing genotype Pro/Pro of TGF-β codon-10 in our population substantiate that both Th1 and Th2 derived cytokines could be an important risk factor for kidney transplant rejection. High producing genotype TT of IL-2 and heterozygous GC of TGF-β codon 25 polymorphism were highly associated with cyclosporine dose requirements in stable renal transplant patients suggesting that recipients may require higher dose with these genotypes. Combined genotype analysis of gene-gene interaction demonstrated synergistic effect of TNF-α with IL-4 and TGF-β increasing the risk for rejection. Our study further suggests that pre-transplantation assessment of this variability could be a powerful tool for better choice of immunosuppressive agents for optimization of individual immunosuppressive therapy. Given the importance of rapidly achieving target blood concentrations after transplantation, further prospective studies should consider the immediate post-graft period and assess the influence of specific polymorphism.

This study was funded by intramural grant of the Institute provided to RDM. Ms. PK. Manchanda is thankful to Council of Scientific and Industrial Research New Delhi for awarding senior research fellowship (SRF). The authors report no conflicts of interest in this work.

###### 

Demographic and clinical details in study population

  Characteristics                                                   RE (N = 34)              DGF (N = 15)           SGF (N = 135)            Controls (N = 180)   P-value (RE and DGF vs SGF)
  ----------------------------------------------------------------- ------------------------ ---------------------- ------------------------ -------------------- -----------------------------
  Age at time of Tx (yrs)                                           19−55 (34.63 ± 9.4)      19−53 (35.5 ± 10.1)    17−64 (36.10 ± 10.3)     15−67 34.96 ± 11.3   NS
  [\*](#tfn3-btt-2-875){ref-type="table-fn"}Gender (M:F)            28:6                     15:0                   118:17                   102:78               NS
  [\*](#tfn3-btt-2-875){ref-type="table-fn"}Donor age (No)                                                                                                        
  \>50                                                              10                       3                      29                       --                   NS
  \<50                                                              24                       12                     106                                           
  CGN^a^ (n = 154)                                                  26                       12                     116                      --                   
  Others[b](#tfn2-btt-2-875){ref-type="table-fn"} (n = 30)          8                        3                      19                       --                   
  [\*](#tfn3-btt-2-875){ref-type="table-fn"}Body weight (kg)        36−70 (53.0 ± 8.5)       33−68 (54.3 ± 7.2)     30−80 (52.9 ± 8.8)       45−79 (55.6 ± 7.9)   NS
  [\*](#tfn3-btt-2-875){ref-type="table-fn"}Cyclosporine dosage,    275−600 (367.4 ± 71.5)   273−600 (358 ± 69.3)   250−700 (386.7 ± 83.5)   --                   NS
  1 Month (mg/d)                                                                                                                                                  
  [\*](#tfn3-btt-2-875){ref-type="table-fn"}Cyclosporine dosage,    100−175 (120.8 ± 20.9)   100−175 (112 ± 20.1)   50−175 (111.5 ± 23.0)    --                   NS
  12 Month (mg/d)                                                                                                                                                 
  [\*](#tfn3-btt-2-875){ref-type="table-fn"}C2 conc (μg/ml), 1 mo   1.64 ± 0.12              1.61 ± 0.11            1.60 ± 0.13              --                   0.032 (RE vs SGF)

**Notes:** ^a^Chronic glomerulonephritis;

^b^Hypertension (12), diabetes mellitus (15) and polycystic kidney disease (2) and Alport syndrome (1);

Mean ± SD; P \> 0.05 (Multinomial logistic analysis); NS, nonsignificant.

###### 

Binary logistic regression analysis of combined effect between SGF and RE of number of mismatches with different genotypes predicting the risk of rejection

  Variable (reference group)                    P-value   OR, 95% CI
  --------------------------------------------- --------- ------------------
  IL-2 (TT)-HLA DR, DQ MM (0--2 MM)                       
  GG                                            0.284     0.313, 0.03−2.61
  TG                                            0.475     0.705, 0.27−1.84
  Il-4 (B2B2)-HLA DR, DQ MM (0--2 MM)                     
  B1B1                                          0.999     --
  B1B2                                          0.771     0.839, 0.25−2.73
  IL-6 (CC)-HLA DR, DQ MM (0--2 MM)                       
  GG                                            0.346     0.658, 0.27−1.57
  GC                                            0.803     1.205, 0.27−5.23
  TNF-α 308 (GG)-HLA DR, DQ MM (0--2 MM)                  
  AA                                            0.946     0.959, 0.28−3.23
  GA                                            0.283     0.548, 0.18−1.64
  TGF-β Cod-10 (TT)-HLA DR, DQ MM (0--2 MM)               
  CC                                            0.745     1.304, 0.26−6.48
  TC                                            0.165     0.522, 0.20−1.30
  TGF-β Cod-25 (GG)-HLA DR, DQ MM (0--2 MM)               
  CC                                            0.806     0.812, 0.15−4.29
  GC                                            0.175     0.433, 0.12−1.45
  TGF-β C-del (CC/CC)-HLA DR, DQ MM (0--2 MM)             
  C/CC                                          0.222     0.379, 0.08−1.79
  HLA DR, DQ MM (0--2 MM)                       0.363     0.682, 0.29−1.55

###### 

Genotype frequencies of IL-2 --330 T/G, IL-4 VNTR, intron 3, IL-6 --174 G/C, TNF-α --308 G/A and TGF-B \[713-8delC, codon 10 T/C (Leu/Pro) and 25 G/C (Arg/Pro)\] gene in transplant recipients (RE, DGF, SGF) and controls

  Gene                                                      Genotype       Controls (180); (%)   Total recipients (184); (%)   RE (34); (%)   DGF (15); (%)   SGF (135); (%)
  --------------------------------------------------------- -------------- --------------------- ----------------------------- -------------- --------------- ----------------
  IL-2 --330                                                TT (HP)        54 (30.0)             69 (37.5)                     16 (47.1)      4 (26.7)        49 (36.3)
  TG (Inm)                                                  100 (55.6)     83 (45.1)             12 (35.3)                     9 (60.0)       62 (45.9)       
  GG (LP)                                                   26 (14.4)      32 (17.4)             6 (17.6)                      2 (13.3)       24 (17.8)       
  IL-4 VNTR, Intron 3                                       B1B1 (HP)      1 (0.5)               8 (4.3)                       4 (11.8)       1 (6.7)         3 (2.2)
  B1B2 (Het)                                                95 (52.8)      60 (32.6)             12 (35.3)                     8 (53.3)       40 (29.6)       
  B2B2 (LP)                                                 84 (46.7)      116 (63.1)            18 (52.9)                     6 (40.0)       92 (68.2)       
  IL-6 --174                                                GG (HP)        109 (68.5)            132 (71.7)                    26 (76.4)      12 (80.0)       94 (69.63)
  GC                                                        53 (24)        23 (12.5)             4 (11.8)                      1 (6.7)        18 (13.33)      
  CC (LP)                                                   18 (7.5)       29 (15.8)             4 (11.8)                      2 (13.3)       23 (17.04)      
  TNF-α (−308)                                              GG             118 (65.6)            45 (24.4)                     2 (5.9)        4 (26.7)        39 (28.9)
  GA                                                        47 (26.1)      84 (45.7)             17 (50.0)                     8 (53.3)       59 (43.7)       
  AA (HP)                                                   15 (8.3)       55 (29.9)             15 (44.1)                     3 (20.0)       37 (27.4)       
  [\*](#tfn8-btt-2-875){ref-type="table-fn"}TGF-B (C-del)   C/CC           27 (15.0)             28 (15.2)                     9 (26.5)       3 (20.0)        16 (11.9)
  CC/CC (HP)                                                153 (85.0)     156 (84.8)            25 (73.5)                     12 (80.0)      119 (88.1)      
  TGF-B (Codon-10)                                          Leu/Leu (HP)   65 (36.1)             29 (15.8)                     2 (5.9)        3 (20.0)        24 (17.8)
  Leu/Pro                                                   92 (51.1)      109 (59.2)            19 (55.9)                     9 (60.0        81 (60.0)       
  Pro/Pro                                                   23 (12.8)      46 (25.0)             13 (38.2)                     3 (20.0)       30 (22.0)       
  TGF-B (Codon-25)                                          Arg/Arg (HP)   120 (66.7)            116 (63.0)                    22 (64.7)      10 (66.7)       84 (62.2)
  Arg/Pro                                                   42 (23.3)      36 (19.6)             6 (17.65)                     2 (13.3)       28 (20.8)       
  Pro/Pro                                                   18 (10.0)      32 (17.4)             6 (17.65)                     3 (20.0)       23 (17.0)       

**Notes:** P-values are for

^\#^total recipients vs Controls; *IL-2*: 0.136; *IL-4*: \<0.001; *IL-6*: \<0.001; TNF-α: \<0.001; TGF-β C-del:

^\*^0.535; TGF-β 10: \<0.001; TGF-β 25: 0.121;

^\#^Pearson Chi-square;

^\*^Fischer exact test.

###### 

Adjusted P-values of IL-2 α330 T/G, IL-4 VNTR, intron 3, IL-6 −174 G/C, TNF-α −308 G/A and TGF-B \[713-8delC, codon 10 T/C (Leu/Pro) and 25 G/C (Arg/Pro)\] gene for multiple comparisons between SGF-RE and SGF-DGF

  Gene                  Genotype   P-value (SGF vs RE)   P-value (SGF vs DGF)
  --------------------- ---------- --------------------- ----------------------
  IL-2 −330             TT         (Ref)                 (Ref)
  TG                    0.665      1.000                 
  GG                    1.000      1.000                 
  IL-4 VNTR, Intron 3   B1B1       0.027                 0.649
  B1B2                  0.102      0.139                 
  B2B2                  (Ref)      (Ref)                 
  IL-6 −174             GG         1.000                 1.000
  GC                    1.000      1.000                 
  CC                    (Ref)      (Ref)                 
  TNF-α (−308)          GG         (Ref)                 (Ref)
  GA                    0.070      1.000                 
  AA                    0.012      1.000                 
  TGF-β (Codon-10)      Leu/Leu    (Ref)                 (Ref)
  Leu/Pro               0.596      1.000                 
  Pro/Pro               0.072      1.000                 
  TGF-β (Codon-25)      Arg/Arg    (Ref)                 (Ref)
  Arg/Pro               1.000      1.000                 
  Pro/Pro               1.000      1.000                 

**Notes:** P = 0.054 and 0.408 for

^\*^SGF vs RE and

^\*^SGF vs DGF respectively for TGF-β C-del;

^\*^Fischer exact test.

###### 

Influence of cytokines genotypes on cyclosporine trough blood levels and dose requirements at one month in stable renal allograft patients

  Genotype         Allelic status (n) dose requirement   (C2 level μg/ml)   p-value^†^
  ---------------- ------------------------------------- ------------------ ------------
  IL-2 −330        T/T (49)                              1.56 ± 0.13        
  T/G              T/G (62)                              1.64 ± 0.12        0.012
                   G/G (24)                              1.63 ± 0.15        
  IL-4             B1/B1 (3)                             1.60 ± 0.14        
  VNTR, Intron3    B1/B2 (40)                            1.61 ± 0.12        0.621
                   B2/B2 (92)                            1.64 ± 0.12        
  Il-6 −174        G/G (94)                              1.56 ± 0.14        
  G/C              G/C (18)                              1.60 ± 0.13        0.363
                   C/C (23)                              1.62 ± 0.13        
  TNF-α −308       G/G (39)                              1.59 ± 0.09        0.209
  G/A              G/A (59)                              1.60 ± 0.16        
                   A/A (37)                              1.63 ± 0.12        
  TGF-β Codon10    T/T (24)                              1.57 ± 0.17        
  T/C              T/C (81)                              1.61 ± 0.13        0.563
                   C/C (30)                              1.63 ± 0.12        
  TGF-β Codon 25   G/G (84)                              1.62 ± 0.15        
  G/C              G/C (28)                              1.56 ± 0.12        0.010
                   C/C (23)                              1.62 ± 0.07        
  TGF-β C-del      CC/CC (119)                           1.60 ± 0.14        0.544
  C-deletion       C/CC (16)                             1.62 ± 0.09        

**Notes:** Values are given as arithmetic mean ± SD;

^\*^P \< 0.05 (^†^Kruskal--Wallis test).

###### 

Distribution of haplotypes of TGF-β (codon 10 and 25) gene in controls, transplant patients, RE and SGF

  Haplotype   Controls (%)   Recipients (%)   RE (%)      SGF (%)     P, OR; 95% CI (^\*^Recipients vs Controls)   P, OR; 95% CI ([\*](#tfn15-btt-2-875){ref-type="table-fn"}RE vs SGF)
  ----------- -------------- ---------------- ----------- ----------- -------------------------------------------- ----------------------------------------------------------------------
  Leu-Arg     88 (48.9)      68 (37.0)        16 (47.1)   49 (36.3)   1.0 (Ref)                                    1.0 (Ref)
  Pro-Arg     54 (30.0)      66 (35.9)        10 (29.4)   49 (36.3)   0.061, 1.582; (0.98−2.55)                    0.297, 0.625; (0.25−1.51)
  Pro-Pro     15 (8.3)       19 (10.3)        1 (2.9)     14 (10.4)   0.195, 1.639; (0.77−3.46)                    0.157, 0.219; (0−0)
  Leu-Pro     23 (12.8)      31 (16.8)        7 (20.6)    23 (17.0)   0.081, 1.744; (0.93−3.26)                    0.892, 0.932; (0.33−2.57)

**Note:** ^\*^Binary Logistic regression analysis.

###### 

Allograft rejection risk for combined effect of cytokine gene polymorphisms between SGF and RE

  Combined genotype                   RE (n = 34); (%)   SGF (n = 135); (%)   [\*](#tfn16-btt-2-875){ref-type="table-fn"}OR at 95% CI; p-value
  ----------------------------------- ------------------ -------------------- ------------------------------------------------------------------
  IL-4^high^-IL-2^low^                7 (20.6)           15 (11.1)            3.920 (1.07−14.2); 0.038
  IL-4^high^-IL-2^high^               10 (29.4)          25 (18.5)            3.360 (1.03−10.9); 0.045
  IL-4^low^-IL-2^high^                12 (35.3)          53 (39.3)            1.902 (0.62−5.8); 0.260
  IL-4^low^-IL-2^low^                 5 (14.7)           42 (31.1)            1.00 (Reference)
  IL-4^high^-IL-6^low^                3 (8.8)            11 (8.1)             1.052 (0.22−4.82); 0.948
  IL-4^high^-IL-6^high^               13 (38.2)          31 (23.0)            1.618 (0.56−4.6); 0.371
  IL-4^low^-IL-6^high^                11 (32.3)          66 (48.9)            0.643 (0.22−1.83); 0.409
  IL-4^low^-IL-6^low^                 7 (20.6)           27 (20.0)            1.00 (Reference)
  IL-4^high^-TNF-α^308/low^           3 (8.8)            6 (4.4)              2.149 (0.43−10.52); 0.345
  IL-4^high^-TNF-α^308/high^          18 (53.0)          32 (23.7)            9.600 (2.05−44.93); 0.004
  IL-4^low^-TNF-α^308/high^           10 (29.4)          65 (48.2)            8.000 (1.09−58.54); 0.041
  IL-4^low^-TNF-α^308/low^            3 (8.8)            32 (23.7)            1.00 (Reference)
  TNF-α^308/low^-TGF-β^10/high^       1 (2.9)            10 (7.4)             1.00 (Reference)
  TNF-α^308/high^-TGF-β^10/low^       29 (85.3)          82 (60.7)            3.537 (0.43−28.84); 0.238
  TNF-α^308/high^-TGF-β^10/high^      2 (5.9)            14 (10.4)            1.429 (0.11−18.00); 0.783
  TNF-α^308/low^-TGF-β^10/low^        2 (5.9)            29 (21.5)            0.690 (−); 0.771
  TNF-α^308/low^-TGF-β^25/high^       1 (2.9)            27 (20.0)            1.00 (Reference)
  TNF-α^308/high^-TGF-β^25/low^       10 (29.4)          39 (28.9)            6.923 (0.83−57.29); 0.073
  TNF-α^308/high^-TGF-β^25/high^      21 (61.8)          57 (42.2)            0.029, 9.947 (1.27−77.86)
  TNF-α^308/low^-TGF-β^25/low^        2 (5.9)            12 (8.9)             0.237, 4.500 (0.37−54.54)
  TNF-α^308/low^-TGF-β^C-del/high^    2 (5.9)            35 (25.9)            1.00 (Reference)
  TNF-α^308/high^-TGF-β^C-del/low^    9 (26.5)           12 (8.9)             0.002, 13.125 (2.47−69.48)
  TNF-α^308/high^-TGF-β^C-del/high^   23 (67.6)          84 (62.2)            0.040, 4.792 (1.07−21.42)
  TNF-α^308/low^-TGF-β^C-del/low^     0 (0.0)            4 (3.0)              --

**Note:** ^\*^Binary logistic regression analysis.
